Vital Therapies, Inc. reported that its bioartifical liver support system, ELAD, produced a significant increase in transplant-free survival. A follow-up to the original China trial, conducted at the three-year point, shows that patients who survive in the short term enjoy extended survival. In a remarkable headline statistic, the follow-up concluded that median survival of the ELAD patients was at least 3 years, while the median survival for the control group was 37 days. More details....